396 results on '"Villeval, Jean-Luc"'
Search Results
2. Exacerbation of thromboinflammation by JAK2V617F mutation worsens the prognosis of cerebral venous sinus thrombosis
3. Lessons from mouse models of MPN
4. Supplementary Table from RETRACTED: In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target
5. Data from RETRACTED: In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target
6. Supplementary Data from RETRACTED: In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target
7. Erythrocyte-derived microvesicles induce arterial spasms in [JAK2.sup.V617F] myeloproliferative neoplasm
8. Comparison of endothelial promoter efficiency and specificity in mice reveals a subset of Pdgfb‐positive hematopoietic cells
9. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice
10. Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN
11. PPAR[gamma] agonists promote the resolution of myelofibrosis in preclinical models
12. SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice
13. Data from In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target
14. Supplementary Data from In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target
15. Supplementary Table from In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target
16. Supplementary Tables 1 to 11 from Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene–Driven Myeloid Leukemia
17. Data from Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene–Driven Myeloid Leukemia
18. Supplementary Figures and Legends from Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene–Driven Myeloid Leukemia
19. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis
20. SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice
21. Animal Models of Myelofibrosis
22. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes
23. The cell cycle regulator CDC25A is a target for JAK2V617F oncogene
24. In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target
25. Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms
26. Notch/Delta4 signaling inhibits human megakaryocytic terminal differentiation
27. SRSF2-P95Hdelays Myelofibrosis Development through Altered JAK/STAT Signaling in JAK2-V617F Megakaryocytes
28. Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines
29. Activating mutations in human acute megakaryoblastic leukemia
30. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
31. JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML
32. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy
33. Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN.
34. Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms
35. Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors
36. Palbociclib Prevents CDK4/6 Dependent-Myeloproliferation and Myelofibrosis
37. In VitroandIn VivoInteractions between Stromal and Leukemic Cells
38. 1017 – INVESTIGATING THE MECHANISMS OF IFNALPHA THERAPY IN JAK2V617F AND CALR MUTATED MYELOPROLIFERATIVE NEOPLASMS
39. Mpl ligand or thrombopoietin: Biological activities
40. Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene–Driven Myeloid Leukemia
41. Gfi-1B plays a critical role in terminal differentiation of normal and transformed erythroid progenitor cells
42. Platelet activation induces metalloproteinase-dependent GP VI cleavage to down-regulate platelet reactivity to collagen
43. Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression
44. Mutations in JAK2V617F homologous domain of JAK genes are uncommon in solid tumors
45. New Insights into the Pathogenesis of JAK2 V617F-Positive Myeloproliferative Disorders and Consequences for the Management of Patients
46. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
47. A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency
48. Disease Phenotype and Clonal Amplification in Calreticulin del52 and ins5 Knock-in Mice Are Dependent on the Type of Mutations and Gene Dosage
49. Regulation of megakaryocytopoiesis and platelet production: Lessons from animal models
50. Ectopic expression of Delta4 impairs hematopoietic development and leads to lymphoproliferative disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.